NCT06347055

Brief Summary

The purpose of the study is to examine the effects of continuous theta burst stimulation (cTBS) on different forms of cognitive control in adults who smoke cigarettes, and to determine if the location where cTBS is delivered may help smokers reduce or quit smoking. Participation in the study will take 3-weeks over 4 visits, with a total time commitment of approximately 12 hours.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
47mo left

Started Oct 2024

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress31%
Oct 2024Apr 2030

First Submitted

Initial submission to the registry

March 20, 2024

Completed
15 days until next milestone

First Posted

Study publicly available on registry

April 4, 2024

Completed
6 months until next milestone

Study Start

First participant enrolled

October 1, 2024

Completed
5.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 25, 2030

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2030

Last Updated

October 1, 2024

Status Verified

September 1, 2024

Enrollment Period

5.5 years

First QC Date

March 20, 2024

Last Update Submit

September 30, 2024

Conditions

Keywords

TobaccoSmokingTMSfMRINicotineCognitive Control

Outcome Measures

Primary Outcomes (1)

  • Acute effects of cTBS on cognitive control

    between-arm differences in neurocognitive task performance as measured by percent correct on an inhibitory control task and self reported craving on a regulation of craving task.

    1 hour after receiving cTBS

Secondary Outcomes (1)

  • Exploratory: Acute effects of cTBS on fMRI brain response

    1 hour after receiving cTBS

Other Outcomes (1)

  • Safety and Tolerability

    24 hours following receipt of cTBS

Study Arms (3)

cTBS to Ventrolateral Prefrontal Cortex

EXPERIMENTAL

Continuous theta-burst stimulation (cTBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. cTBS will be applied to the ventrolateral prefrontal cortex.

Device: Repetitive Transcranial Magnetic Stimulation (rTMS)

cTBS to Dorsomedial Prefrontal Cortex

EXPERIMENTAL

Continuous theta-burst stimulation (cTBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. cTBS will be applied to the dorsomedial prefrontal cortex.

Device: Repetitive Transcranial Magnetic Stimulation (rTMS)

cTBS to Vertex

EXPERIMENTAL

Continuous theta-burst stimulation (cTBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. cTBS will be applied to the vertex.

Device: Repetitive Transcranial Magnetic Stimulation (rTMS)

Interventions

Continuous theta burst rTMS

Also known as: cTBS
cTBS to Dorsomedial Prefrontal CortexcTBS to Ventrolateral Prefrontal CortexcTBS to Vertex

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Nicotine Dependence as measured by: Smoke ≥ 8 cigarettes/day for ≥ 2 yrs, expired carbon monoxide (CO) concentration of ≥ 10 ppm, positive urine cotinine test and FTND score ≥ 3 Or ≥ 15 uses of electronic cigarette/day for ≥ 1 year, positive urine cotinine test, and PS-ECDI score ≥ 3
  • English Fluency
  • Functional Vision (with corrective lenses as needed)

You may not qualify if:

  • Use of psychotropic and antiepileptic medications in the last month
  • Presence of an untreated illness or serious medical condition
  • History of major neurological illness
  • Contraindication to TMS (history of neurological disorder or seizure, increased intracranial pressure, brain surgery, or head trauma with loss of consciousness for \>15 min., implanted electronic device, metal in the head) or MRI.
  • Any use of substances that lower seizure threshold.
  • Current or past psychosis
  • Electroconvulsive therapy in the past 6 months
  • Unstable cardiac disease or hypertension, severe renal or liver insufficiency, or sleep apnea
  • BAC greater than 0.0.
  • Positive urine pregnancy test
  • Any other concern that in the investigator's opinion would impact participant safety, study instruction compliance, or confound the interpretation of the study results.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Health Neuroscience Center

Columbia, Missouri, 65203, United States

RECRUITING

MeSH Terms

Conditions

Tobacco Use DisorderSmoking

Interventions

Transcranial Magnetic Stimulation

Condition Hierarchy (Ancestors)

Substance-Related DisordersChemically-Induced DisordersMental DisordersBehavior

Intervention Hierarchy (Ancestors)

Magnetic Field TherapyTherapeutics

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

March 20, 2024

First Posted

April 4, 2024

Study Start

October 1, 2024

Primary Completion (Estimated)

March 25, 2030

Study Completion (Estimated)

April 30, 2030

Last Updated

October 1, 2024

Record last verified: 2024-09

Locations